## Alex Duval

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7915462/publications.pdf

Version: 2024-02-01

25 papers 2,969 citations

19 h-index 24 g-index

28 all docs

 $\begin{array}{c} 28 \\ \text{docs citations} \end{array}$ 

28 times ranked

4731 citing authors

#	Article	IF	CITATIONS
1	Consequences of the Hsp $110$ DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh $2$ -deficient mice. Cellular and Molecular Life Sciences, 2022, 79, .	5.4	O
2	Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. European Journal of Cancer, 2021, 144, 9-16.	2.8	40
3	Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer., 2021, 9, e001903.		15
4	Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Cancers, 2021, 13, 1149.	3.7	30
5	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical Cancer Research, 2021, 27, 4768-4780.	7.0	25
6	Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Gastroenterology, 2021, 161, 814-826.e7.	1.3	36
7	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	27.8	374
8	MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. Bulletin Du Cancer, 2019, 106, 119-128.	1.6	61
9	Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncology, 2019, 5, 551.	7.1	178
10	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. Journal of the National Cancer Institute, 2018, 110, 68-77.	6.3	89
11	Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8. Annals of Oncology, 2018, 29, viii18.	1.2	11
12	Targeting nonsense-mediated mRNA decay in colorectal cancers with microsatellite instability. Oncogenesis, 2018, 7, 70.	4.9	58
13	Identification of Positively and Negatively Selected Driver GeneÂMutations Associated With Colorectal Cancer With Microsatellite Instability. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 277-300.	4.5	15
14	Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. European Journal of Cancer, 2017, 86, 266-274.	2.8	65
15	HSP110 promotes colorectal cancer growth through STAT3 activation. Oncogene, 2017, 36, 2328-2336.	5 <b>.</b> 9	53
16	Extracellular HSP110 skews macrophage polarization in colorectal cancer. Oncolmmunology, 2016, 5, e1170264.	4.6	33
17	<i>HSP110</i> T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. Journal of Medical Genetics, 2016, 53, 377-384.	3.2	46
18	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study. Journal of Clinical Oncology, 2015, 33, 4176-4187.	1.6	515

## ALEX DUVAL

#	Article	IF	CITATION
19	Patients With Colorectal Tumors With Microsatellite Instability andÂLarge Deletions in HSP110 T17 Have Improved Response to 5-Fluorouracil–Based Chemotherapy. Gastroenterology, 2014, 146, 401-411.e1.	1.3	62
20	Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nature Medicine, 2011, 17, 1283-1289.	30.7	137
21	Microsatellite Instability in Colorectal Cancer: Time to Stop Hiding!. Oncotarget, 2011, 2, 826-827.	1.8	11
22	Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. British Journal of Cancer, 2010, 103, 1840-1845.	6.4	51
23	Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status of Human Tumors. Journal of Clinical Oncology, 2006, 24, 241-251.	1.6	212
24	Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology, 2002, 123, 1804-1811.	1.3	535
25	Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Research, 2002, 62, 2447-54.	0.9	307